AlphAIAlphAI — Financial news for AI agents
investing.comOCT 222 min read$ARGX

argenx ADR earnings missed by $0.10, revenue topped estimates

argenx ADR (ARGX) reported Q3 EPS of $7.80, missing estimates by $0.10, but revenue of $1.72B exceeded expectations of $1.65B. The stock closed at $890.05, down 3.07% over 3 months but up 9.59% year-over-year. InvestingPro rates its financial health as 'great performance'.

Original reporting
investing.com
Published Oct 22, 2026, 7:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 7:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ARGX
Bearish
high confidence
Mentioned
$ARGX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ARGXBearishMed
01

Why it matters

The EPS miss, though small, may prompt short‑term sell‑offs, while the revenue beat offers a modest positive note.

02

Market read

First report of argenx's quarterly earnings; relevant for biotech traders and short‑term investors.

03

What to watch

Potential pipeline developments or upcoming trial data not mentioned may mitigate short-term downside.

Relevance 7/10Novelty 7/10Timing: after earnings release

Background

argenx ADR (NASDAQ: ARGX) is a mid‑cap biotech company. The article provides its Q3 earnings numbers and brief performance metrics.

Company-level read

Ticker impact

$ARGXBearishHigh confidence
Context

argenx ADR reported Q3 EPS of $7.80, missing estimates by $0.10 and revenue of $1.72B beating consensus, a fresh earnings disclosure.

Expected impact

downward pressure as market prices in the EPS miss

Evidence & confidence

The EPS miss, though modest, signals weaker profitability than expected; investors typically react negatively to any earnings shortfall.

Market effects

Sector

Biotech sector may see modest pullback as earnings miss highlights valuation sensitivity.

Regional

US biotech stocks could face slight pressure in early trade.

Global

Limited to investors tracking biotech earnings; no broad market effect.

Counterpoint

What could challenge this read

The revenue beat could offset the EPS miss, supporting a hold or buy for long-term investors.

Key entities

  • company
    argenx ADR

    Biotech firm reporting Q3 earnings.

Read at source← All news

StoryArgenx posts Q3 2026 sales surge and pipeline milestones while integrating Forte acquisition

Also covered by

6 outlets

Related articles

OCT 22
$ARGXHighAI 8/10

Key facts: ARGX Q3 Sales $1.7B; FDA Priority Review for VYVGART Hytrulo

argenx (ARGX) reported Q3 2026 sales of $1.7B, up 54% YoY, with net profit of $506M. FDA granted priority review for VYVGART Hytrulo, with a PDUFA date set for February 2027. The company also announced positive Phase 3 results for VYVGART in IMNM and dermatomyositis, and plans to file an sBLA for IMNM by year-end. ARGX closed the Forte Biosciences deal, spending about $2.1B, and has cash of near $3.7B as of September 30, 2026.

tradingview.com2 min
OCT 22
$ARGXMed

Argenx says Vyvgart sales rose 54% in third quarter

Argenx reported a 54% increase in Vyvgart sales to $1.7B in Q3, treating generalized myasthenia gravis. Operating profit was $486M, below estimates. The company completed a $2.2B acquisition of Forte Biosciences, adding a drug for vitiligo and celiac disease. Operating margin declined to 28.2% due to acquisition costs, and R&D expenses are expected to reach $4B by 2026.

marketscreener.com2 min
OCT 22
$ARGXHighAI 8/10

argenx SE Reports Strong Q3 Earnings, Shares Trade Well Below GF

argenx SE (ARGX) reported Q3 2026 earnings per share of $7.80, up from $5.18 a year ago, with product sales growing 53% YoY to $1.72B. The company trades at $890.05, 44.3% below its GF Value of $1,597.83, indicating undervaluation. ARGX has a GF Score of 79, reflecting strong financial health and growth. Institutional investors show confidence, with eight gurus holding the stock.

gurufocus.com3 min
OCT 22
$ARGXHighAI 8/10

Argenx Earnings Up In Q3

Argenx (ARGX) reported Q3 earnings: net income rose to $506M from $344M YoY, EPS $7.80 vs. $5.18, operating profit $486M vs. $346M. Operating income increased to $1.75B from $1.15B. The company expects $4B in R&D and SG&A expenses for 2026. ARGX closed 2.34% higher at $890.05 on Nasdaq.

rttnews.com2 min